New hope for advanced bladder cancer patients in major trial
NCT ID NCT07393542
Summary
This study compares a new two-drug combination (SHR-A2102 plus adebrelimab) against standard chemotherapy for people with advanced bladder cancer that hasn't been treated before. The trial aims to see if the new combination helps patients live longer without their cancer getting worse. Researchers will enroll 462 adults with advanced bladder cancer who haven't received prior treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
Contact
Conditions
Explore the condition pages connected to this study.